A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2018-03-05
Target enrollment:
Participant gender:
Summary
This is a Phase 2, 3-week, single-center, double-blind, randomized, two-arm, vehicle
controlled study, with each individual receiving both active and vehicle treatment.
Approximately 30 subjects with moderate atopic dermatitis will receive topically applied
ATx201 CREAM 2% and matching vehicle once daily for 3 weeks (5 mg/cm2/day), without
occlusion. ATx201 and vehicle will be applied on two separate target lesions of moderate
atopic dermatitis (lesions of at least 3 × 3 cm, excluding the face, scalp, genitals, hands,
and feet, ideally from the same anatomical location).